Sign In
Buy BIIB
$207.94
+1.66 (+0.80%)
At Close: Aug 07, 2026
Biogen Inc. (BIIB) Gains As Market Dips: What You Should Know
11:00pm, Monday, 06'th Feb 2023 Zacks Investment Research
Biogen Inc. (BIIB) closed at $288.28 in the latest trading session, marking a +1.64% move from the prior day.
Sage Therapeutics-Biogen Partnered Depression Candidate Under Priority FDA Review, Analyst Says Its 'Incrementally Positive'
05:14pm, Monday, 06'th Feb 2023 Benzinga
The FDA has accepted for review a marketing application seeking approval for Sage Therapeutics Inc (NASDAQ: SAGE) and Biogen Inc's (NASDAQ: BIIB) zuranolone for major depressive disorder (MDD) a
Biogen and Sage Therapeutics Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression
11:30am, Monday, 06'th Feb 2023 GlobeNewswire Inc.
CAMBRIDGE, Mass., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Sage Therapeutics, Inc. (Nasdaq: SAGE) announced the U.S. Food and Drug Administration (FDA) has accepted the fili
Biogen: What To Do Ahead Of Q4 2022 Financial Report
07:12am, Monday, 06'th Feb 2023 Seeking Alpha
Biogen's business focuses on developing and commercializing drugs aimed at treating patients living with neurological and neurodegenerative diseases. Find out why BIIB stock is a Hold.
New Alzheimer's drug shows some promise, but has big price tag
10:39am, Thursday, 02'nd Feb 2023 MarketWatch
How to alleviate ravages of the disease without bankrupting individuals or Medicare program?
Biogen Inc. (BIIB) Dips More Than Broader Markets: What You Should Know
11:00pm, Monday, 30'th Jan 2023 Zacks Investment Research
Biogen Inc. (BIIB) closed at $285.94 in the latest trading session, marking a -1.43% move from the prior day.
Lecanemab Receives Priority Review Status in Japan
11:30pm, Sunday, 29'th Jan 2023 GlobeNewswire Inc.
TOKYO and CAMBRIDGE, Mass., Jan. 29, 2023 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massa
Biogen (BIIB) & Eisai's Lecanemab Secures EMA's MAA Acceptance
02:57pm, Friday, 27'th Jan 2023 Zacks Investment Research
Biogen (BIIB) and Eisai jointly announce that EMA accepts lecanemab's marketing authorization application (MAA) for the treatment of patients with early-stage Alzheimer's disease, for review.
Eli Lilly (LLY) to Report Q4 Earnings: What's in the Cards?
01:23pm, Friday, 27'th Jan 2023 Zacks Investment Research
Higher demand for its key drugs is likely to have offset generic competition for several other drugs and may have boosted Lilly's (LLY) fourth-quarter sales.
Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer’s Disease Accepted by European Medicines Agency
11:30pm, Thursday, 26'th Jan 2023 GlobeNewswire Inc.
TOKYO and CAMBRIDGE, Mass., Jan. 26, 2023 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massa
This "Golden" Technical Indicator is Triggering Across the Market
01:36pm, Thursday, 26'th Jan 2023 Zacks Investment Research
A Golden Cross is a simple, yet effective technical indicator. Andrew Rocco explains how to use it and relates it back to the current market.
Is Biogen Stock a Buy Now?
12:30pm, Thursday, 26'th Jan 2023 The Motley Fool
Its new drug might succeed where the company faltered in 2021.
This "Golden" Technical Indicator is Triggering Across the Market
09:47am, Thursday, 26'th Jan 2023
A Golden Cross is a simple, yet effective technical indicator. Andrew Rocco explains how to use it and relates it back to the current market.
Is Biogen Stock a No-Brainer Buy After Eli Lilly's Alzheimer's Disease Setback?
10:57am, Wednesday, 25'th Jan 2023 The Motley Fool
Lilly's FDA rejection puts Biogen and its partner Eisai in the driver's seat in the Alzheimer's disease drug market.
Biogen Inc. (BIIB) Stock Moves -0.02%: What You Should Know
11:00pm, Tuesday, 24'th Jan 2023 Zacks Investment Research
In the latest trading session, Biogen Inc. (BIIB) closed at $291.88, marking a -0.02% move from the previous day.
